Susanna Mandruzzato

Susanna Mandruzzato

Associate Professor

Telefono: +39 0498215898

Phone lab: +39 0498215843


Pharmaceutical Chemistry degree
PhD in Oncology, University of Padova

- Institute of General Pathology, University of Padova, Italy, 1989 – 1990
- Institute of Oncology, Chair of Immunology, University of Padova, Italy, 1990- 1994
- Investigator, Ludwig Institute for Cancer Research (Brussels Branch) - Brussels,
Belgium 1994 -1997
- Assistant Professor of Immunology, Department of Surgery, Oncology and Gastroenterology, University of Padova, 2006-2018

- Role of adaptive immune response in different mouse models and implications for adoptive cell therapy. (Rosato et al., Int J Cancer, 1992; Zanovello et al., Cancer Immunol Immunother., 1992; Mandruzzato et al., Pharmacological Res., 1192; Pollis et al. Pharmacological Res., 1992; Rosato et al., Leukemia/s, 1992; Pollis et al. Leukemia/s, 1992; Mandruzzato et al., Cancer Res., 1994; Rosato et al., Int J Cancer, 1995; Rosato et al., Int J Cancer, 1996)

- Tumor antigens recognized by cytotoxic T lymphocytes: molecular identification and characterization of their role in cancer patients. (Herman et al., Immunogenetics, 1996; Mandruzzato et al., J. Exp. Med.,1997; Dalerba et al., Int J Cancer, 2001; Zambon et al., Cancer, 2001; Mandruzzato et al., J Immunol, 2002, Rosato et al., Int J Cancer).

- Analysis of genes and miRNA expression in tumors and their role in tumor progression. (Wang et al., J Transl Med., 2004; Basil et al., Cancer Res., 2006; Mandruzzato et al., J Transl Med., 2006; Indraccolo et al., J Immunol., 2007; Mandruzzato Adv Exp Med Biol., 2007; Crende et al., Am J Pathol., 2013; Pizzini et al., BMC Genomics, 2013; Bisognin et al., Mol Onc., 2014; Perilli et al., Oncotarget, 2014; Perilli et al., Genomics Data, 2014).

- Immune-evasion in cancer: role of myeloid-derived suppressor cells (MDSC). (Bronte et al., Immunol Invest, 2006; Mandruzzato et al., J. Immunol., 2009; Peranzoni et al., Curr Opin Immunol 2010; Marigo et al., Immunity, 2010; Chioda et al., Cancer Metastasis Rev, 2011; Solito et al., J Leukoc Biol., 2011; Solito et al., Blood, 2011; Montero et al., J Immunother., 2012; Walter et al., Nature Medicine, 2012; Solito et al., Immunol Invest, 2012; Ugel et al., Cell Reports, 2012; Zoso et al., Eur. J. Immunol., 2014; Mazza et al. Genomics Data, 2014; Solito et al., Annals of the NY Academy of Sc, 2014; Damuzzo et al., Cytometry part B, 2015; Ugel et al., J. Clin. Invest., 2015; Pinton et al., Oncotarget, 2015; Mandruzzato et al., Cancer Immunol. Immunother., 2016; Solito et al., J. of Pathol., 2017, Pinton et al., OncoImmunology, 2018).

1. Mandruzzato S., Brasseur F., Andry G., Boon T. and van der Bruggen P.  A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma.  Journal of Experimental Medicine, 186 : 785-793, 1997

2. Mandruzzato, S. Solito, S., Falisi, E., Francescato, S., Chiarion-Sileni, V., Mocellin, S., Zanon, A., Rossi, C. R., Nitti. D., Bronte, A. Zanovello, P. IL4Ra+ myeloid-derived suppressor cell expansion in cancer patients. Journal of Immunology 2009; 182 : 6562-6568.

3. Marigo, I., Bosio, E., Solito, S., Mesa-Pardillo, C., Gomez Fernandez, A., Dolcetti, L., Ugel, S., Sonda, N., Bicciato, S., Falisi, E., Calabresi, F., Zanovello, P., Basso, G., Cozzi, E., Mandruzzato, S., Bronte, V. Tumor-Induced +Tolerance and Immune Suppression Depend on the C/EBPbeta Transcription Factor. Immunity, 2010; 32(6):790-802.

4. Solito, S., Falisi, E., Diaz-Montero, CM., Doni, A., Pinton, L., Rosato, A., Francescato, S., Basso, G., Zanovello, P., Oniescu, G., Garrett-Mayer, E., Montero, AJ., Bronte, V., Mandruzzato, S. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood, 2011;118(8):2254-65.

5. Bisognin, A., Pizzini, S., Perilli, L., Esposito, G., Mocellin, S., Nitti, D., Zanovello, P., Bortoluzzi, S., Mandruzzato, S. An integrative framework identifies alternative splicing events in colorectal cancer development. Molecular Oncology, 2014, Feb 8 (1):129-141.

6. Ugel, S., De Sanctis, F., Mandruzzato, S., Bronte, V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. Journal of Clinical Investigations, 2015; 125(9): 6635-76

7. Mandruzzato, S. , Brandau S., Britten C.M., Bronte V., Damuzzo V., Gouttefangeas C., Maurer D., Ottensmeier C.H., Van der Burg S., Welters M.J.P., Walter S. Towards harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. Cancer Immunology Immunotherapy. 2016 Feb;65(2):161-

8. Bronte, V., Brandau, S., Chen, S.H., Colombo, M.P., Frey, A.F., Greten, T.F., Mandruzzato, S., Murray, P., Ochoa, A., Ostrand-Rosenberg, S., Rodriguez, P.C., Sica, A., Umansky, V., Vonderheide, R.H., Gabrilovich, D. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nature Communications, 2016; Jul 6;7:12150. doi: 10.1038/ncomms12150.

9. Damuzzo, V., Solito, S., Pinton, L., Carrozzo, E., Valpione, S., Pigozzo, J., Arboretti Giancristofaro, R., Chiarion-Sileni, V., Mandruzzato, S. Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. OncoImmunology, 2016 Nov 1;5(12):e1249559.

10. Pinton, L., Solito, S., Masetto, E., Vettore, M., Della Puppa, A., Mandruzzato, S. Suppressive innate immunity dominates tumor microenvironment in early stage meningiomas. 2018, OncoImmunology.

- AIRC Investigator Grant IG 2012. Project title: The dynamic interplay of MDSCs with T cells: envisioning new approaches for cancer immunotherapy. € 270.000 (2013-2015)

- EURONANOMED II - Joint Transnational Call for Proposals (2013) Project title: Nano-Immuno-CHEmotherapy, Acronym: NICHE. € 197.000(2014-2016)

- AIRC Investigator Grant IG 2016. Project title: “Unveiling the role of myeloid-derived suppressor cells in checkpoint blockade therapy”.   € 245.000 (2016-2018)

TRANSCAN-2: “Immunology and immunotherapy of cancer: strengthening the translational aspects”. Project title: Deciphering immune response against Glioblastoma to find new Targets. Acronym: Immunoglio.  € 300.000 (2017-2019)